Arovella Therapeutics Ltd (ALA) - Total Assets

Latest as of December 2025: AU$20.25 Million AUD ≈ $14.33 Million USD

Based on the latest financial reports, Arovella Therapeutics Ltd (ALA) holds total assets worth AU$20.25 Million AUD (≈ $14.33 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

Arovella Therapeutics Ltd - Total Assets Trend (2001–2025)

This chart illustrates how Arovella Therapeutics Ltd's total assets have evolved over time, based on quarterly financial data. Also see ALA stock market capitalisation for the company's overall valuation and market capitalisation.

Arovella Therapeutics Ltd - Asset Composition Analysis

Current Asset Composition (June 2025)

Arovella Therapeutics Ltd's total assets of AU$20.25 Million consist of 98.0% current assets and 2.0% non-current assets. Review Arovella Therapeutics Ltd total liabilities to assess the company's total debt and financial obligations.

Asset Category	Amount (AUD)	% of Total Assets
Cash & Equivalents	AU$20.88 Million	96.7%
Accounts Receivable	AU$0.00	0.0%
Inventory	AU$0.00	0.0%
Property, Plant & Equipment	AU$430.57K	2.0%
Intangible Assets	AU$0.00	0.0%
Goodwill	AU$0.00	0.0%

Asset Composition Trend (2001–2025)

This chart illustrates how Arovella Therapeutics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Arovella Therapeutics Ltd stock quote for real-time trading data and today's change.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Arovella Therapeutics Ltd's current assets represent 98.0% of total assets in 2025, an increase from 71.0% in 2001.
Cash Position: Cash and equivalents constituted 96.7% of total assets in 2025, up from 70.7% in 2001.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 28.0% in 2001.
Asset Diversification: The largest asset category is cash and equivalents at 96.7% of total assets.

Arovella Therapeutics Ltd Competitors by Total Assets

Key competitors of Arovella Therapeutics Ltd based on total assets are shown below.

Company	Country	Total Assets
argenx NV ADR NASDAQ:ARGX	USA	$10.03 Billion
Asymchem Laboratories Tian Jin Co Ltd SHE:002821	China	CN¥20.70 Billion
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	China	CN¥8.59 Billion
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	USA	$2.19 Billion
Tubize-Fin BR:TUB	Belgium	€1.99 Billion
Galapagos N.V. AS:GLPG	Netherlands	€3.37 Billion
Neuren Pharmaceuticals Ltd AU:NEU	Australia	AU$331.25 Million
Latigo Biotherapeutics, Inc. Common Stock NASDAQ:LTGO	USA	$64.76 Million

Arovella Therapeutics Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	15.36	11.24	3.79
Quick Ratio	15.36	11.24	3.78
Cash Ratio	15.00	10.82	3.60
Working Capital	AU$18.55 Million	AU$11.12 Million	AU$4.24 Million

Arovella Therapeutics Ltd - Advanced Valuation Insights

This section examines the relationship between Arovella Therapeutics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	4.86
Latest Market Cap to Assets Ratio	2.30
Asset Growth Rate (YoY)	62.6%
Total Assets	AU$21.60 Million
Market Capitalization	$49.61 Million USD

Valuation Analysis

Premium Asset Valuation: The market values Arovella Therapeutics Ltd's assets at a significant premium (2.30x), suggesting investors see substantial growth potential or unique competitive advantages.

Rapid Asset Growth: Arovella Therapeutics Ltd's assets grew by 62.6% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Arovella Therapeutics Ltd (2001–2025)

The table below shows the annual total assets of Arovella Therapeutics Ltd from 2001 to 2025.

Year	Total Assets	Change
2025-06-30	AU$21.60 Million ≈ $15.28 Million	+62.60%
2024-06-30	AU$13.28 Million ≈ $9.40 Million	+142.82%
2023-06-30	AU$5.47 Million ≈ $3.87 Million	-40.61%
2022-06-30	AU$9.21 Million ≈ $6.52 Million	-13.80%
2021-06-30	AU$10.69 Million ≈ $7.56 Million	+59.33%
2020-06-30	AU$6.71 Million ≈ $4.75 Million	-58.73%
2019-06-30	AU$16.25 Million ≈ $11.50 Million	-2.34%
2018-06-30	AU$16.64 Million ≈ $11.78 Million	-16.85%
2017-06-30	AU$20.02 Million ≈ $14.16 Million	+2.56%
2016-06-30	AU$19.52 Million ≈ $13.81 Million	-14.48%
2015-06-30	AU$22.82 Million ≈ $16.15 Million	+12.16%
2014-06-30	AU$20.35 Million ≈ $14.40 Million	+89.65%
2013-06-30	AU$10.73 Million ≈ $7.59 Million	+9.99%
2012-06-30	AU$9.75 Million ≈ $6.90 Million	-27.88%
2011-06-30	AU$13.53 Million ≈ $9.57 Million	+13.64%
2010-06-30	AU$11.90 Million ≈ $8.42 Million	-28.35%
2009-06-30	AU$16.61 Million ≈ $11.75 Million	+3.41%
2008-06-30	AU$16.06 Million ≈ $11.37 Million	-23.50%
2007-06-30	AU$21.00 Million ≈ $14.86 Million	+26.27%
2006-06-30	AU$16.63 Million ≈ $11.77 Million	+11.22%
2005-06-30	AU$14.95 Million ≈ $10.58 Million	-7.11%
2004-06-30	AU$16.10 Million ≈ $11.39 Million	+245.95%
2003-06-30	AU$4.65 Million ≈ $3.29 Million	+47.97%
2002-06-30	AU$3.14 Million ≈ $2.22 Million	-48.60%
2001-06-30	AU$6.12 Million ≈ $4.33 Million	--

About Arovella Therapeutics Ltd

AU:ALA Australia Biotechnology

Market Cap

$49.61 Million

AU$70.11 Million AUD

Market Cap Rank

#22011 Global

#774 in Australia

Share Price

AU$0.06

Change (1 day)

-1.69%

52-Week Range

AU$0.06 - AU$0.10

All Time High

AU$0.57